HK1181389A1 - Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof - Google Patents

Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof

Info

Publication number
HK1181389A1
HK1181389A1 HK13108816.0A HK13108816A HK1181389A1 HK 1181389 A1 HK1181389 A1 HK 1181389A1 HK 13108816 A HK13108816 A HK 13108816A HK 1181389 A1 HK1181389 A1 HK 1181389A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
amide derivative
amide
Prior art date
Application number
HK13108816.0A
Other languages
English (en)
Chinese (zh)
Inventor
金用鎰
金京洙
章起寧
金辰哲
朴宰賢
禹鍾守
Original Assignee
韓美科學株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 韓美科學株式會社 filed Critical 韓美科學株式會社
Publication of HK1181389A1 publication Critical patent/HK1181389A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK13108816.0A 2010-06-11 2013-07-29 Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof HK1181389A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100055549A KR101217526B1 (ko) 2010-06-11 2010-06-11 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
PCT/KR2011/004271 WO2011155793A2 (en) 2010-06-11 2011-06-10 Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof

Publications (1)

Publication Number Publication Date
HK1181389A1 true HK1181389A1 (en) 2013-11-08

Family

ID=45098550

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13108816.0A HK1181389A1 (en) 2010-06-11 2013-07-29 Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof

Country Status (26)

Country Link
US (1) US20130071452A1 (de)
EP (1) EP2580206B1 (de)
JP (1) JP5852105B2 (de)
KR (1) KR101217526B1 (de)
CN (1) CN102933573B (de)
AR (1) AR081870A1 (de)
AU (1) AU2011262662B2 (de)
BR (1) BR112012031510B1 (de)
CA (3) CA2801631C (de)
CL (1) CL2012003487A1 (de)
CO (1) CO6620015A2 (de)
DK (1) DK2580206T3 (de)
ES (1) ES2556457T3 (de)
HK (1) HK1181389A1 (de)
IL (1) IL223543A (de)
MA (1) MA34368B1 (de)
MX (1) MX2012014440A (de)
MY (1) MY164015A (de)
NZ (1) NZ605601A (de)
PE (1) PE20130236A1 (de)
PL (1) PL2580206T3 (de)
SG (1) SG185661A1 (de)
TW (1) TWI424995B (de)
UA (1) UA109281C2 (de)
WO (1) WO2011155793A2 (de)
ZA (1) ZA201300241B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
WO2018213770A1 (en) * 2017-05-19 2018-11-22 Regents Of The University Of Minnesota Therapeutic methods
KR102227486B1 (ko) * 2017-06-30 2021-03-12 롯데정밀화학 주식회사 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법
CN112088000A (zh) 2018-03-27 2020-12-15 得克萨斯州大学系统董事会 具有针对携带her2外显子19突变之癌细胞的抗肿瘤活性的化合物
AU2019292184A1 (en) 2018-06-25 2020-12-17 Spectrum Pharmaceuticals, Inc. Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
WO2020053816A1 (en) * 2018-09-14 2020-03-19 Hanmi Pharmaceutical Co., Ltd. Crystalline forms of a quinazole compound and its hydrochloride salts
US11365189B2 (en) 2019-04-25 2022-06-21 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of tyrosine kinase
CN114144514A (zh) 2019-05-09 2022-03-04 富士胶片细胞动力公司 产生肝细胞的方法
JP2022553744A (ja) * 2019-10-24 2022-12-26 ハンミ ファーマシューティカル カンパニー リミテッド がん細胞の成長を阻害するアミド誘導体を含む医薬調製物およびそれを含有する医薬品

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR980008219A (ko) * 1996-07-16 1998-04-30 김상응 안정화된 주사제용 약제학적 조성물
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
RU2002110461A (ru) * 1999-09-21 2004-03-10 Астразенека Аб (Se) Производные хиназолина и их применение в качестве фармацевтических веществ
US20070037837A1 (en) * 2003-09-19 2007-02-15 Hennequin Laurent Francois A Quinazoline derivatives
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
AU2004276055A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
JP5649157B2 (ja) * 2009-08-01 2015-01-07 住友電気工業株式会社 半導体素子およびその製造方法

Also Published As

Publication number Publication date
US20130071452A1 (en) 2013-03-21
CA3127906A1 (en) 2011-12-15
MY164015A (en) 2017-11-15
CA3012771C (en) 2021-10-12
BR112012031510B1 (pt) 2021-06-22
MA34368B1 (fr) 2013-07-03
KR20110135685A (ko) 2011-12-19
EP2580206A4 (de) 2014-01-22
SG185661A1 (en) 2012-12-28
CA2801631C (en) 2018-09-04
CN102933573A (zh) 2013-02-13
WO2011155793A3 (en) 2012-04-26
RU2013100943A (ru) 2014-07-20
CL2012003487A1 (es) 2013-02-22
MX2012014440A (es) 2013-02-26
CA3012771A1 (en) 2011-12-15
IL223543A (en) 2017-02-28
TW201204711A (en) 2012-02-01
PE20130236A1 (es) 2013-03-18
JP5852105B2 (ja) 2016-02-03
PL2580206T3 (pl) 2016-03-31
NZ605601A (en) 2014-11-28
UA109281C2 (uk) 2015-08-10
ES2556457T3 (es) 2016-01-18
DK2580206T3 (en) 2016-01-11
WO2011155793A2 (en) 2011-12-15
CA2801631A1 (en) 2011-12-15
BR112012031510A2 (pt) 2016-11-08
CN102933573B (zh) 2014-12-24
AU2011262662A1 (en) 2013-01-31
CO6620015A2 (es) 2013-02-15
AU2011262662B2 (en) 2015-06-25
JP2013531648A (ja) 2013-08-08
EP2580206A2 (de) 2013-04-17
KR101217526B1 (ko) 2013-01-02
EP2580206B1 (de) 2015-09-23
ZA201300241B (en) 2014-03-26
TWI424995B (zh) 2014-02-01
AR081870A1 (es) 2012-10-24

Similar Documents

Publication Publication Date Title
HUS000509I2 (hu) Abemaciklib vagy egy gyógyászatilag elfogadható sója
HK1181389A1 (en) Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof
IL245326B (en) pharmaceutical preparation
HRP20181170T1 (hr) Novi derivat cefalosporina i njegov farmaceutski pripravak
IL224976A (en) Converted history of 1h - indazole and a pharmaceutical preparation containing them
IL225457A0 (en) Pharmaceutical composition
LT2619182T (lt) Farmacinė kompozicija
ZA201207839B (en) Pharmaceutical composition comprising a pyrimidineone derivative
EP2594554A4 (de) Biarylamidderivate bzw. pharmazeutisch zulässiges salz daraus
EP2554169A4 (de) Pharmazeutisches präparat mit einem phenylalaninderivat
PT2579858E (pt) Composição farmacêutica que contém ivabradina
EP2588106A4 (de) Verzögert freigesetzte pharmazeutische zusammensetzung mit pramipexol oder einem pharmazeutisch zulässigen salz davon mit erhöhter stabilität
ZA201301920B (en) Pharmaceutical composition
GB201010453D0 (en) Pharmaceutical composition
HRP20141240T1 (en) An inhalable pharmaceutical composition
EP2545046A4 (de) Zyklisches n-acyl-aminderivat oder pharmazeutisch zulässiges salz daraus
HU1000299D0 (en) Nanostructured atorvastatin, its pharmaceutically acceptable salts and pharmaceutical compositions containing them and process for their preparation
IL221501A (en) Medicinal product containing miramistine
GB201001911D0 (en) Pharmaceutical composition
EP2789613A4 (de) 1,4-dihydro-naphthyridin-derivat sowie pharmazeutische zusammensetzung damit und ihre verwendung
EP2628488A4 (de) Pharmazeutische zusammensetzung mit verzögerter freisetzung
GB201019775D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230608